Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study

Purpose: To assess the noninferiority, efficacy, and safety of degarelix in achieving and maintaining testosterone at castrate levels (≤0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with prostate cancer (PCa). Methods: A Phase III, open-label, multicenter, single-arm trial was condu...

Full description

Bibliographic Details
Main Authors: Dalsan You, Byung Ha Chung, Sang Eun Lee, Choung-Soo Kim
Format: Article
Language:English
Published: Elsevier 2015-03-01
Series:Prostate International
Subjects:
Androgen deprivation therapy
Degarelix
Korean
Prostate cancer
Testosterone
Online Access:http://www.sciencedirect.com/science/article/pii/S2287888215000069

Internet

http://www.sciencedirect.com/science/article/pii/S2287888215000069

Similar Items